5月7日 - ** 基因疗法生产商 Sarepta Therapeutics SRPT.O盘前股价下跌 19.83% 至 37.48 美元
** 该公司预计2025年产品净营收为23亿至26亿美元，此前预期为29亿至31亿美元
** 在美国FDA任命 (link) Vinay Prasad为生物制品评估与研究中心主任后，Sarepta公司股价周二承压 (link)。
** 新任命、第一季度业绩不佳和预期下调 "引发了投资者对 SRPT 即将面临的监管/商业/财务困境的担忧"--BMO Capital Markets
** 我们看到了通往复苏的漫长隧道，但相信尽头会有曙光--券商
** 截至上一交易日收盘，该公司股价年累计下跌约 62
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.